Patent: 10,301,361
✉ Email this page to a colleague
Summary for Patent: 10,301,361
| Title: | α-hemolysin variants with altered characteristics |
| Abstract: | Described herein are variants of alpha-hemolysin having at least one mutation selected from T12R, T12K, N17R, N17K or combinations of T12 and N17 mutations. The variants in some embodiments may further comprise H144A. The α-hemolysin variants have a decreased time to thread. |
| Inventor(s): | Michael Dorwart, Daniel Korenblum |
| Assignee: | Roche Sequencing Solutions Inc |
| Application Number: | US14/924,861 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,301,361
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.s.a., Inc. | VPRIV | velaglucerase alfa | For Injection | 022575 | February 26, 2010 | ⤷ Start Trial | 2035-10-28 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,301,361
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016069806 | ⤷ Start Trial |
| United States of America | 2024409590 | ⤷ Start Trial |
| United States of America | 2023295247 | ⤷ Start Trial |
| United States of America | 2020339634 | ⤷ Start Trial |
| United States of America | 2019225656 | ⤷ Start Trial |
| United States of America | 2017088588 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
